Oncotherics Poland S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-10-27
Share capital
104,649.20 PLN
Activity description

Oncotherics Poland develops hypoxia-activated prodrugs designed to target treatment-resistant cancer cells and complement established therapies. Its lead clinical programme is AQ4N for newly diagnosed glioblastoma, while OCT1002 is a separately patented asset in advanced preclinical development.

Registered address
ul. Profesora Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-70859-89994-HFTDG-27

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 1 of 4 financial statements was filed late (for 2024, 17 days late). All were audited by a statutory auditor.

  • 2025not filed
  • 202401/08/2025
  • 202305/07/2024
  • 202213/07/2023
  • 202114/07/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Division · Scientific research and development1,458 / 1,943
Top 75%
Voivodeship · Małopolskie38,398 / 46,048
Top 83%
Country · Poland415,581 / 496,474
Top 84%

Results vs industry

Revenue
This companyUSD 7.57kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -74.15kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 64.27kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 1.70mMedianUSD 134.71kAverageUSD 3.04m

Offer

  • Cancer drug research
  • Cancer drug development
  • Hypoxia-activated prodrugs
  • Glioblastoma therapies
  • Preclinical testing

Websites

  • oncotherics.comOncoTherics | AQ4N and OCT1002 Cancer Therapeutics
    WordPressGoogle AnalyticsGoogle Tag ManagerNginx

Authorized Representatives

Kinga Stanisława Drechny-Mucha age 49 – Attorney-in-fact (sole)
Stefan Ogrodzinski age 62 – President of the Management Board

Manner of representation

Each member of the management board is authorized to perform legal acts and submit declarations of will on behalf of the company independently.

Supervisory board

Roland Kozlowski age 63 – Supervisory Board Member
Laurence Patterson – Supervisory Board Member
Paul Smith – Supervisory Board Member

Bank accounts

Registered as a VAT taxpayer on 2019-12-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $2,977,240.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$5,075
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$3,823
Aid for research and development projects: industrial research
$2.1M

European Funds

ProjectEU co-financing
Development of an innovative hypoxia-activated substance for cancer therapy
$3.1M

Competitors

Name
Personather sp. z o.o.
Orphinic Scientific S.A.
Onconick sp. z o.o.
Biolabic sp. z o.o.
Inventro S.A.
Nanovelos S.A.
4cell Therapies S.A.
Bioinfobank Capital sp. z o.o.
Synerga.Fund S.A.
Passio Human Microbiome sp. z o.o.

Change history

DateEvent
2022-03-15Share capital increase
2021-10-27Entered in the register

FAQ

Last updated: 2026-04-01